| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
In RAW 264.7 cells, schisandrin (10-100 μM; 2 h pretreatment) dose-dependently suppresses LPS-stimulated NO generation, iNOS protein, and mRNA expression [1]. In LPS-stimulated RAW 264.7 macrophages, schisandrin (25–100 μM; 2 hours pretreatment) suppresses prostaglandin E2 synthesis, COX-2 protein, and mRNA expression [1]. SK-HEP-1, SNU-638, and T47D cell proliferation is inhibited by schisandrin, with IC50 values of 42.0, 53.1, and 40.0 μM, respectively [3]. Schisandrin (10–60 μM; 48 hours) preferentially reverses MCF-7/DOX resistance and amplifies apoptosis elicited by doxorubicin [4].
|
|---|---|
| ln Vivo |
In mice, schisandrin (10–100 mg/kg; single intraperitoneal injection) decreases paw edema brought on by carrageenan and prevents peritoneal vascular permeability brought on by acetic acid [1]. Schisandrin (1–10 mg/kg; single oral dosage) dramatically improves oxotremorine-induced tremor in rats and overcomes scopolamine-induced deficits in spatial memory and passive avoidance responses [2].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: RAW 264.7 Macrophage Tested Concentrations: 12.5, 25, 50, 100 μM Incubation Duration: Pretreatment for 2 hrs (hours), then incubated with LPS (1 μg/mL) for 18 hrs (hours) Experimental Results: iNOS protein expression demonstrated significant in a dose-dependent manner. Dramatically inhibits COX-2 protein expression. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice (4 weeks) were intraperitoneally (ip) (ip) injected with λ-carrageenan [1] in the right hind paw.
Doses: 100, 200 mg/kg. Route of Administration: single ip. Experimental Results: Inhibited paw edema by 33.43% (100 mg /kg) and 57.38 % (200 mg/kg) at 3 hrs (hrs (hours)). |
| References |
[1]. Guo LY, et, al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol. 2008 Sep 4;591(1-3):293-9.
[2]. Egashira N, et, al. Schizandrin reverses memory impairment in rats. Phytother Res. 2008 Jan;22(1):49-52. [3]. Min HY, et, al. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg Med Chem Lett. 2008 Jan 15;18(2):523-6. [4]. Zhang ZL, et, al. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer. 2018 Mar;25(2):233-242. |
| Molecular Formula |
C24H32O7
|
|---|---|
| Molecular Weight |
432.51
|
| Exact Mass |
432.2148
|
| CAS # |
7432-28-2
|
| Related CAS # |
Schisandrin B;61281-37-6;Schisandrin C;61301-33-5;Schisandrin A;61281-38-7
|
| SMILES |
O([H])[C@]1(C([H])([H])[H])C([H])([H])C2=C([H])C(=C(C(=C2C2=C(C(=C(C([H])=C2C([H])([H])[C@]1([H])C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| Synonyms |
Magnolia Vine Gomisins Schizandrin
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1 mg/mL (~2.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.28 mg/mL (0.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3121 mL | 11.5604 mL | 23.1209 mL | |
| 5 mM | 0.4624 mL | 2.3121 mL | 4.6242 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3121 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
